Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Want to see NAUT full AI Analyst Report?
NAUT Stock Chart & Stats
$3.03
$0.07(3.48%)
At close: 4:00 PM EST
$3.03
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.62 - $4.31
Previous CloseN/A
Volume21.91K
Average Volume (3M)394.63K
Market Cap
$302.45M
Enterprise Value$316.69M
Total Cash (Recent Filing)$95.87M
Total Debt (Recent Filing)$28.87M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 04, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding127,078,860
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-199.43
Enterprise Value/Ebitda-5.64
Forecast
1Y Price Target
$4.00Price Target Upside32.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Platform Technical ValidationPublic debut of the Voyager with strong community reception provides durable scientific validation of the core instrument. That endorsement supports customer confidence, partner collaborations, and long-term adoption, strengthening the company's competitive position for instrument placements and consumables revenue.
Assay Readiness And Early AccessLaunching Early Access and having a validated Tau assay establishes a practical path to customer engagement and iterative product improvement. Early program feedback accelerates commercial readiness, reduces technical risk pre-GA, and builds initial reference data supporting future recurring consumables revenue.
Healthy Cash Runway And Conservative LeverageA material cash balance combined with reduced burn and guidance to 2027 gives management time to commercialize. Conservative debt (low leverage) limits near-term financing pressure, enabling the company to invest in instrument launches and commercial build without immediate dilution or distress.
Bears Say
Pre-commercial With No RevenueZero trailing revenue and sustained large operating losses mean the business lacks recurring product sales today. This keeps the company dependent on financing, delays unit-economics validation, and creates execution risk as commercial milestones must materialize to achieve sustainable margins.
High And Worsening Cash BurnSignificant negative operating and free cash flow, with free cash flow deteriorating sharply, indicates the company is burning cash faster than before. That trend raises probability of future financings, potential dilution, and compresses time available to execute on commercialization plans without altering strategy or spending.
No Sales Organization / Commercialization RiskAbsent an established salesforce, converting Early Access interest into instrument preorders and consumables adoption will depend on new hires and go-to-market execution. Building commercial capability is time-consuming and costly, creating timing and execution risk for the 2026–2027 revenue ramp.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $4.31 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $302.45M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Aug 04, 2026 which is in 75 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Apr 28, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.025.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.14.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 127,078,860 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went up 0.778%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (32.01% Upside)
$4.00 (32.01% Upside)
Insider Transactions
Bought Shares
Worth $65.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-35.04%
Trailing 12-Months
Asset Growth
-21.92%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful technical progress, strong external validation, the successful public debut of the Voyager instrument, the early launch of an Early Access Program (Tau assay) and disciplined expense reductions that improved cash burn and extended runway through 2027. Offsetting these positives are limited near-term revenue (modest 2026 services revenue targeted at ~$0.5M), no current sales organization, and a planned increase in 2026 operating expenses and cash burn as the company invests to advance commercialization. On balance, the developments point to a company transitioning from development to early customer engagement with tangible validation and a clear commercialization timeline, though revenue and commercial execution risks remain in the near term.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$4.00
▲(32.01% Upside)
Technical Analysis
Ownership Overview
35.31% Insiders
2.58% Mutual Funds
34.94% Other Institutional Investors
25.10% Public Companies and
Individual Investors